"We are very pleased to establish this strategic collaboration with TD2, as we see significant synergies between Inform Genomics’ proprietary technology and analytics along with TD2’s world-class oncology
miRagen and Servier Research will continue preclinical research and development on multiple cardiovascular programs targeting microRNAs, including miR-208 and miR-15. Servier will lead the global clinical development and
The dispensary is a well-known, high volume dispensary licensed in medical and recreational marijuana sales. The 100-day pilot program is designed to test for compliance and tracking integration
BL-1110 may also be developed for the treatment of scleroderma, an autoimmune disease characterized by a hardening and tightening of the skin and connective tissues. The compound, which
The collaboration between ChromaDex and St. Jude will focus on screening ChromaDex’s natural product libraries against certain biological assays and tumor models with the intent of identifying high
The patent covers methods for treating ulcerative colitis or Crohn’s disease using placenta-derived cells. This patent has already been issued to Pluristem in South Africa and is currently
Upon the successful closing of the tender offer, stockholders of Idenix will receive $24.50 in cash for each share of Idenix common stock validly tendered and not validly
The tablet formulation of oral CR845 was formulated utilizing Enteris’ proprietary oral delivery technology under a Manufacturing and Clinical Supply Agreement. The agreement with Cara Therapeutics is representative
This settlement provides a license to Perrigo and Catalent to sell limited units of Perrigo’s generic version of the product for an initial period beginning Dec. 19, 2016
In partnership with Sanofi, Merrimack completed an extensive Phase II program for MM-121 which was designed to assess the role of ErbB3 in a number of cancer indications
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.